Immunic Competitors

Immunic (NASDAQ:IMUX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Immunic and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Immunic and Phathom Pharmaceuticals' revenue, earnings per share and valuation.

Immunic is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Immunic has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Immunic and Phathom Pharmaceuticals, as provided by MarketBeat.

Immunic presently has a consensus target price of $59.5556, indicating a potential upside of 354.62%. Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 48.83%. Given Immunic's stronger consensus rating and higher possible upside, research analysts clearly believe Immunic is more favorable than Phathom Pharmaceuticals.

Institutional and Insider Ownership

41.3% of Immunic shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 12.1% of Immunic shares are owned by company insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunic beats Phathom Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunic and Kronos Bio, as provided by MarketBeat.

Immunic currently has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 117.14%. Given Immunic's higher probable upside, research analysts clearly believe Immunic is more favorable than Kronos Bio.

Profitability

This table compares Immunic and Kronos Bio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Immunic and Kronos Bio's revenue, earnings per share and valuation.

Institutional & Insider Ownership

41.3% of Immunic shares are held by institutional investors. 12.1% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Immunic beats Kronos Bio on 4 of the 6 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Institutional and Insider Ownership

56.6% of Omeros shares are held by institutional investors. Comparatively, 41.3% of Immunic shares are held by institutional investors. 11.3% of Omeros shares are held by insiders. Comparatively, 12.1% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Omeros and Immunic's top-line revenue, earnings per share and valuation.

Immunic has lower revenue, but higher earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Omeros and Immunic, as provided by MarketBeat.com.

Omeros presently has a consensus price target of $23.40, indicating a potential upside of 27.45%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Omeros.

Profitability

This table compares Omeros and Immunic's net margins, return on equity and return on assets.

Risk & Volatility

Omeros has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Summary

Immunic beats Omeros on 9 of the 13 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Immunic and Stoke Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Immunic and Stoke Therapeutics, as reported by MarketBeat.com.

Immunic currently has a consensus target price of $59.5556, indicating a potential upside of 354.62%. Stoke Therapeutics has a consensus target price of $64.3333, indicating a potential upside of 110.65%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunic is more favorable than Stoke Therapeutics.

Insider and Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. 12.1% of Immunic shares are owned by company insiders. Comparatively, 54.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Immunic has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Earnings and Valuation

This table compares Immunic and Stoke Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Stoke Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Stoke Therapeutics on 6 of the 11 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Y-mAbs Therapeutics and Immunic's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Y-mAbs Therapeutics and Immunic, as provided by MarketBeat.

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 124.84%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Y-mAbs Therapeutics.

Insider and Institutional Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Immunic shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Immunic's gross revenue, earnings per share (EPS) and valuation.

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Y-mAbs Therapeutics on 8 of the 11 factors compared between the two stocks.

Mersana Therapeutics (NASDAQ:MRSN) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Mersana Therapeutics and Immunic's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Mersana Therapeutics and Immunic, as provided by MarketBeat.

Mersana Therapeutics currently has a consensus price target of $26.1667, indicating a potential upside of 65.30%. Immunic has a consensus price target of $59.5556, indicating a potential upside of 354.62%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Mersana Therapeutics.

Insider and Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. 5.3% of Mersana Therapeutics shares are owned by insiders. Comparatively, 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Mersana Therapeutics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Immunic has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Earnings & Valuation

This table compares Mersana Therapeutics and Immunic's gross revenue, earnings per share (EPS) and valuation.

Mersana Therapeutics has higher revenue and earnings than Immunic. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Summary

Immunic beats Mersana Therapeutics on 7 of the 13 factors compared between the two stocks.